Free Trial
NASDAQ:ATXI

Avenue Therapeutics (ATXI) Stock Price, News & Analysis

Avenue Therapeutics logo
$0.46 +0.01 (+1.10%)
As of 08/1/2025 03:18 PM Eastern

About Avenue Therapeutics Stock (NASDAQ:ATXI)

Key Stats

Today's Range
$0.46
$0.49
50-Day Range
$0.20
$0.53
52-Week Range
$0.17
$3.54
Volume
4,231 shs
Average Volume
189,155 shs
Market Capitalization
$1.46 million
P/E Ratio
0.03
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Avenue Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

ATXI MarketRank™: 

Avenue Therapeutics scored higher than 47% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Avenue Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avenue Therapeutics is 0.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avenue Therapeutics is 0.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.

  • Price to Book Value per Share Ratio

    Avenue Therapeutics has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avenue Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.55% of the outstanding shares of Avenue Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 1.20%, indicating that investor sentiment is improving.
  • Dividend Yield

    Avenue Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Avenue Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.55% of the outstanding shares of Avenue Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Avenue Therapeutics has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avenue Therapeutics has recently decreased by 1.20%, indicating that investor sentiment is improving.
    • Insider Buying vs. Insider Selling

      In the past three months, Avenue Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 1.80% of the stock of Avenue Therapeutics is held by insiders.

    • Percentage Held by Institutions

      Only 17.34% of the stock of Avenue Therapeutics is held by institutions.

    • Read more about Avenue Therapeutics' insider trading history.
    Receive ATXI Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Avenue Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    ATXI Stock News Headlines

    One stock to replace Nvidia
    Investing Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another to rival Tesla… and a third to upset Nvidia. These little-known stocks are poised to overtake the three reigning tech darlings in a move that could completely reorder the top dogs of the stock market. Eric Fry gives away names, tickers and full analysis in this first-ever free broadcast.
    See More Headlines

    ATXI Stock Analysis - Frequently Asked Questions

    Avenue Therapeutics' stock was trading at $2.00 at the beginning of 2025. Since then, ATXI stock has decreased by 77.0% and is now trading at $0.46.

    Avenue Therapeutics, Inc. (NASDAQ:ATXI) posted its quarterly earnings results on Friday, August, 9th. The company reported ($6.43) EPS for the quarter, missing the consensus estimate of ($1.05) by $5.38.

    Shares of Avenue Therapeutics reverse split before market open on Friday, April 26th 2024.The 1-75 reverse split was announced on Friday, April 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 26th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

    Avenue Therapeutics (ATXI) raised $30 million in an initial public offering on Tuesday, June 27th 2017. The company issued 5,000,000 shares at $5.00-$7.00 per share. Oppenheimer acted as the underwriter for the IPO and National Securities Corp. was co-manager.

    Shares of ATXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Avenue Therapeutics investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), CrowdStrike (CRWD) and Novo Nordisk A/S (NVO).

    Company Calendar

    Last Earnings
    8/09/2024
    Today
    8/02/2025
    Next Earnings (Estimated)
    8/07/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:ATXI
    CIK
    1644963
    Fax
    N/A
    Employees
    4
    Year Founded
    2015

    Profitability

    EPS (Trailing Twelve Months)
    ($7.49)
    Trailing P/E Ratio
    0.03
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$10.38 million
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    -471.57%
    Return on Assets
    -296.50%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    2.70
    Quick Ratio
    2.70

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $1.92 per share
    Price / Book
    0.24

    Miscellaneous

    Outstanding Shares
    3,183,000
    Free Float
    2,017,000
    Market Cap
    $1.46 million
    Optionable
    Not Optionable
    Beta
    -0.08

    Social Links

    Metaverse Stocks And Why You Can't Ignore Them Cover

    Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

    Get This Free Report

    This page (NASDAQ:ATXI) was last updated on 8/2/2025 by MarketBeat.com Staff
    From Our Partners